Back to News
Market Impact: 0.15
Outlook Therapeutics Appoints Kevin Lundquist As CFO Ahead Of U.S. LYTENAVA Launch; Stock Up
Source: Nasdaq
Company FundamentalsManagement & Governance
Outlook Therapeutics (OTLK) appointed Kevin Lundquist as Chief Financial Officer effective September 1, 2026, replacing Lawrence Kenyon. The update is a management change with limited disclosed financial impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
OTLK0.15
More News
- ‘If nothing is done, it’s almost inevitable’: Ukraine’s Yuriy Ryzhenkov on why steelmaking is on the brink of collapse as Russian bombing intensifies
- Why is LG Innotek stock plunging today?
- TotalEnergies, KKR expand U.S. solar venture with 700 MW addition
- TSMC expected to report sixth straight quarter of record profit thanks to AI boom
- Vår Energi cuts 2026 output forecast; Q3 production at 369,000 boepd
- CXMT: How big is its market threat to Samsung, SK Hynix and Micron?
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- The Great Divergence: North American Banking at the Crossroads of Monetary Policy and Agentic AI (Q4 2025 Bank Earnings)
- AI for M&A Target Screening: From Universe to Deal File